Mechanisms involved in attenuated cardio-protective role of ischemic preconditioning in metabolic disorders

Perfusion (United Kingdom)

Volumn 30, Issue 2, 2015, Pages 94-105

  Rana, A ^a   Goyal, N ^a   Ahlawat, A ^a   Jamwal, S ^a   Reddy, B V K ^a   Sharma, Saurabh ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

diabetic myocardium; glycogen synthase kinase 3 ; hyperlipidemic myocardium; ischemic preconditioning; PI3K Akt pathway; PTEN

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCITONIN GENE RELATED PEPTIDE; GLYCOGEN SYNTHASE KINASE 3BETA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; MUSCLE PROTEIN;

DIABETES MELLITUS; HEART INFARCTION; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; ISCHEMIC PRECONDITIONING; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; HEART INFARCTION PREVENTION; HEART MUSCLE; METABOLIC DISEASES; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY;

HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; METABOLIC DISEASES; MUSCLE PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIUM;

EID: 84924854748     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659114536760     Document Type: Review

References (136)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 ; 74: 1124-1136
2. Balakumar P, Singh H, Singh M, et al. The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacol Res. 2009 ; 60: 18-23
3. Schott RJ, Rohmann S, Braun ER, et al. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res. 1990 ; 66: 1133-1142
4. Cohen MV, Liu GS, Downey JM. Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits. Circulation. 1991 ; 84: 341-349
5. Steenbergen C, Fralix TA, Murphy E. Role of increased cytosolic free calcium concentration in myocardial ischemic injury. Basic Res Cardiol. 1993 ; 88: 456-470
6. Burns PG, Krukenkamp IB, Caldarone CA, et al. Does cardiopulmonary bypass alone elicit myoprotective preconditioning?. Circulation. 1995 ; 92: II447 - II451
7. Liang BT, Gross GJ. Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels. Circ Res. 1999 ; 84: 1396-400
8. Kunuthur SP, Mocanu MM, Hemmings BA, et al. The Akt1 isoform is an essential mediator of ischaemic preconditioning. J Cell Mol Med. 2012 ; 16: 1739-1749
9. Ikonomidis JS, Shirai T, Weisel RD, et al. Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C. Am J Physiol. 1997 ; 272: H1220 - H1230
10. Wu ZK, Laurikka J, Saraste A, et al. Cardiomyocyte apoptosis and ischemic preconditioning in open heart operations. Ann Thorac Surg. 2003 ; 76: 528-534
11. Fernández-Avilés F, San Román JA, García-Frade J, et al. Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res. 2004 ; 95: 742-748
12. Granfeldt A, Lefer DJ, Vinten-Johansen J. Protective ischaemia in patients: preconditioning and postconditioning. Cardiovasc Res. 2009 ; 83: 234-246
13. Shen YT, Depre C, Yan L, et al. Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning. Circulation. 2008 ; 118: 1961-1969
14. Balakumar P, Sharma NK. Healing the diabetic heart: does myocardial preconditioning work?. Cell Signal. 2012 ; 24: 53-59
15. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: new strategies for cardioprotection. Diabetes Obes Metab. 2008 ; 10: 451-459
16. Penna C, Mancardi D, Raimondo S, et al. The paradigm of postconditioning to protect the heart. J Cell Mol Med. 2008 ; 12: 435-458
17. Laude K, Favre J, Thuillez C, et al. NO produced by endothelial NO synthase is a mediator of delayed preconditioning-induced endothelial protection. Am J Physiol-Heart C. 2003 ; 284: H2053 - H2060
18. Kudo M, Wang Y, Xu M, et al. Adenosine A(1) receptor mediates late preconditioning via activation of PKC-delta signaling pathway. Am J Physiol-Heart C. 2002 ; 283: H296-301
19. Cohen MV, Downey JM. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol. 2008 ; 103: 203-215
20. Yao Z, Gross GJ. Role of nitric oxide, muscarinic receptors, and the ATP-sensitive K+ channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. Circ Res. 1993 ; 73: 1193-1201
21. Sharma A, Singh M. Role of angiotensin in cardioprotective effect of ischemic preconditioning. J Cardiovasc Pharm. 1999 ; 33: 772-778
22. Goto M, Liu Y, Yang XM, et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 1995 ; 77: 611-621
23. Hampton CR, Shimamoto A, Rothnie CL, et al. HSP70.1 and 703 are required for late-phase protection induced by ischemic preconditioning of mouse hearts. Am J Physiol-Heart C. 2003 ; 285: H866 - H874
24. Wenxia C, Mehrotra S, Danser AH, et al. The role of calcitonin generated peptide (CGRP) in ischemic preconditioning in isolated rat heart. Eur J Pharmacol. 2006 ; 531: 246-253
25. Millar CG, Baxter GF, Thiemermann C. Protection of the myocardium by ischaemic preconditioning: mechanisms and therapeutic implications. Pharmacol Therapeut. 1996 ; 69: 143-151
26. Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol. 1997 ; 29: 207-216
27. Ohnuma Y, Miura T, Miki T, et al. Opening of mitochondrial KATP channel occurs downstream of PKC-e activation in the mechanism of preconditioning. Am J Physiol-Heart C. 2002 ; 283: H440 - H447
28. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003 ; 83: 1113-1151
29. Zhu M, Jianhua F, Eliana L, et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Circ res. 2006 ; 72: 152-162
30. Andrukhiv A, Costa AD, West IC, et al. Opening mitoKATP increases superoxide generation from complex I of electron transport chain. Am J Physiol-Heart C. 2006 ; 291: H2067 - H2074
31. Costa AD, Jakob R, Costa CL, et al. The mechanism by which the mitochondrial ATP-sensitive K+ channel opening and H2O2 inhibit the mitochondrial permeability transition. J Biol Chem. 2006 ; 281: 20801-20808
32. Hausenloy DJ, Wynne AM, Yellon DM. Ischemic preconditioning targets the reperfusion phase. Basic Res Cardiol. 2007 ; 102: 445-452
33. Wu ZK, Iivainen T, Pehkonen E, et al. Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization. Circulation. 2002 ; 106: 3091-3096
34. Ban K, Cooper AJ, Samuel S, et al. Phosphatidylinositol-3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res. 2008 ; 103: 643-653
35. Kunuthur SP, Mocanu MM, Hemmings BA, et al. The Akt1 isoform is an essential mediator of ischaemic preconditioning. JCMM. 2012 ; 16: 1739-1749
36. Krieg T, Qin Q, Philipp S, et al. Acetylcholine and bradykinin trigger preconditioning in the heart through a pathway that includes Akt and NOS. Am J Physiol-Heart C. 2004 ; 287: H2606 - H2611
37. Tong H, Chen W, Steenbergen C, et al. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res. 2000 ; 87: 309-315
38. Mocanu MM, Bell RM, Yellon DM. PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol. 2002 ; 34: 661-668
39. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Circ Res. 2006 ; 70: 240-253
40. da Silva R, Grampp T, Pasch T, et al. Differential activation of mitogen-activated protein kinases in ischemic and anesthetic preconditioning. Anesthesiology. 2004 ; 100: 59-69
41. Hattori R, Maulik N, Otani H, et al. Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol. 2001 ; 33: 1929-1936
42. Lecour S, Suleman N, Deuchar GA, et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation. 2005 ; 112: 3911-3918
43. Wojtovich AP, Brookes PS. The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels. Basic Res Cardiol. 2009 ; 104: 121-129
44. Hausenloy DJ, Maddock HL, Baxter GF, et al. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Circ Res. 2002 ; 55: 534-543
45. Yellon DM, Latchman DS. Stress proteins and myocardial protection. J Mol Cell Cardiol. 1992 ; 24: 113-124
46. Hoshida S, Kuzuya T, Fuji H, et al. Sublethal ischemia alters myocardial antioxidant activity in canine heart. Am J Physiol-Heart C. 1993 ; 264: H33 - H39
47. Murry CE, Richard VJ, Reimer KA. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res. 1990 ; 66: 913-931
48. Nakamura M, Wang NP, Zhao ZQ, et al. Preconditioning decreases Bax expression, PMN accumulation and apoptosis in reperfused rat heart. Circ Res. 2002 ; 45: 661-670
49. Akao M, Ohler A, O'Rourke B, et al. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res. 2001 ; 88: 1267-1275
50. Garlid KD, Dos Santos P, Xie ZJ, et al. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K+ channel in cardiac function and cardioprotection. Biochim Biophys Acta. 2003 ; 1606: 1-21
51. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res. 2004 ; 94: 7-16
52. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Circ Res. 2004 ; 61: 372-385
53. Testai L, Rapposelli S, Calderone V. Cardiac ATP-sensitive potassium channels: a potential target for an anti-ischaemic pharmacological strategy. Cardiovasc Hematol Agents Med Chem. 2007 ; 5: 79-90
54. Javadov SA, Clarke S, Das M, et al. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol. 2003 ; 549: 513-524
55. Argaud L, Gateau-Roesch O, Muntean D, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol. 2005 ; 38: 367-374
56. Li YZ, Ge X, Liu XH. The cardioprotective effect of postconditioning is mediated by ARC through inhibiting mitochondrial apoptotic pathway. Apoptosis. 2009 ; 14: 164-172
57. Kersten JR, Schmeling TJ, Orth KG, et al. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol. 1998 ; 275: H721 - H725
58. Sasaki H, Ogawa K, Shimizu M, et al. The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in type 2 diabetes mellitus rats. Int Heart. 2007 ; 48: 623-635
59. Katakam PVG, Jordan JE, Snipes JA, et al. Myocardial preconditioning against ischemia - reperfusion injury is in Zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp Physiol. 2007 ; 292: 920-926
60. Andersen A, Povlsen JA, Bøtker HE, et al. Right ventricular hypertrophy and failure abolish cardioprotection by ischaemic pre-conditioning. Eur J Heart Fail. 2013 ; 15: 1208-1214
61. Ebrahim Z, Yellon DM, Baxter GF. Attenuated cardioprotective response to bradykinin, but not classical ischaemic preconditioning, in DOCA-salt hypertensive left ventricular hypertrophy. Pharmacol Res. 2007 ; 55: 42-48
62. Giricz Z, Lalu MM, Csonka C, et al. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther. 2006 ; 316: 154-161
63. Yadav HN, Singh M, Sharma PL. Modulation of the cardioprotective effect of ischemic preconditioning in hyperlipidaemic rat heart. Eur J Pharmacol. 2010 ; 643: 78-83
64. Pepe S. Dysfunctional ischemic preconditioning mechanisms in aging. Cardiovasc Res. 2001 ; 49: 11-14
65. Tang XL, Takano H, Xuan YT, et al. Hypercholesterolemia abrogates late preconditioning via a tetrahydrobiopterin-dependent mechanism in conscious rabbits. Circulation. 2005 ; 112: 2149-2156
66. Balakumar P, Rohilla A, Singh G, et al. Modulation of cardioprotective effect of ischemic pre- and postconditioning in the hyperhomocysteinemic rat heart. Method Find Exp Clin. 2009 ; 31: 71-79
67. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2004 ; 404: 787-790
68. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007 ; 59: 418-458
69. Monteiro P, Goncalves L, Providência LA. Diabetes and cardiovascular disease: the road to cardioprotection. Heart. 2005 ; 91: 1621-1625
70. Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3β. Diabetes. 2007 ; 56: 787-795
71. Verma S, Maitland A, Weisel R, et al. Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocytes injury: reversal with endothelin antagonism. J Thorac Cardiovasc Surg. 2002 ; 123: 1120-1124
72. Balakumar P, Rohilla A, Singh M. Pre-conditioning and postconditioning to limit ischemia-reperfusion-induced myocardial injury: what could be the next footstep?. Pharmacol Res. 2008 ; 57: 403-412
73. Song T, Peng YF, Guo SY, et al. Brief small intestinal ischemia lessens renal ischemia-reperfusion injury in rats. Comp Med. 2007 ; 57: 200-205
74. Siddall HK, Warrell CE, Yellon DM, et al. Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, is using a congenital model of PTEN haploinsufficiency. Basic Res Cardiol. 2008 ; 103: 560-568
75. Oudit GY, Penninger JM. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res. 2009 ; 82: 250-260
76. Song P, Wu Y, Xu J, et al. Reactive nitrogen species induced by hyperglycemia suppresses Akt signaling and triggers apoptosis by upregulating phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) in an LKB1-dependent manner. Circulation. 2007 ; 116: 1585-1595
77. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. The Lancet. 1997 ; 349: 1436-1442
78. Ma XJ, Zhang XH, Luo M, et al. Effects of preconditioning and postconditioning on emergency percutaneous coronary intervention in patients with acute myocardial infarction. Zhonghua Yi Xue Za Zhi. 2007 ; 87: 114-117
79. Kupai K, Csonka C, Fekete V, et al. Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. Am J Physiol. 2009 ; 297: H1729 - H1735
80. Ghaboura N, Tamareille S, Ducluzeau PH, et al. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling. Basic Res Cardiol. 2011 ; 106: 147-162
81. Mocanu MM, Yellon DM. PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury?. Br J Pharmacol. 2007 ; 150: 833-838
82. Raphael J, Gozal Y, Navot N, et al. Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling. J Cardiovasc Pharmacol. 2010 ; 55: 348-357
83. Tsang A, Hausenloy DJ, Mocanu MM, et al. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005 ; 54: 2360-2364
84. Pain T, Yang XM, Critz SD, et al. Opening of mitochondrial KATP channels triggers the preconditioned state by generating free radicals. Circ Res. 2000 ; 87: 460-466
85. Del Valle HF, Lascano EC, Negroni JA. Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels. Cardiovasc Res. 2002 ; 55: 642-659
86. Hassouna A, Loubani M, Matata BM, et al. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc Res. 2006 ; 69: 450-458
87. Wang J, Li J. Activated protein C: a potential cardioprotective factor against ischemic injury during ischemia/reperfusion. Am J Transl Res. 2009 ; 1: 381
88. Balaraman Y, Limaye AR, Levey AI, et al. Glycogen synthase kinase 3β and Alzheimer's disease: pathophysiological and therapeutic significance. Cell Mol Life Sci. 2006 ; 63: 1226-1235
89. Xu FF, Liu XH, Cai LR. Role of hypoxia-inducible factor-1alpha in the prevention of cardiomyocyte injury induced by hypoxic preconditioning. Sheng Li Xue Bao. 2004 ; 56: 609-614
90. Sotníková R, Nedelcevová J, Navarová J, et al. Protection of the vascular endothelium in experimental situations. Interdiscip Toxicol. 2011 ; 4: 20-26
91. Lu R, Hu CP, Peng J, et al. Role of calcitonin gene-related peptide in ischaemic preconditioning in diabetic rat hearts. Clin Exp Pharmacol Physiol. 2001 ; 28: 392-396
92. Ebel D, Toma O, Appler S, et al. Ischemic preconditioning phosphorylates mitogen-activated kinases and heat shock protein 27 in the diabetic rat heart. Horm Metab Res. 2009 ; 41: 10-15
93. Hotta H, Miura T, Miki T, et al. Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts. Circ Res. 2010 ; 106: 129-132
94. Forlani S, Tomai F, De Paulis R, et al. Preoperative shift from glibenclamide to insulin is cardioprotective in diabetic patients undergoing coronary artery bypass surgery. J Cardiovasc Surg. 2004 ; 45: 117-122
95. Kehl F, Krolikowski JG, Weihrauch D, et al. N-acetylcysteine restores isoflurane-induced preconditioning against myocardial infarction during hyperglycemia. Anesthesiology. 2003 ; 98: 1384-1390
96. Kim HS, Cho JE, Hong SW, et al. Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart. Physiol Res. 2010 ; 59: 347-356
97. Han JS, Yan DM, Zhu HY, et al. Diabetes counteracts the protective effect of the diazoxide preconditioning on ischemic reperfused rat heart. Zhonghua Wai Ke Za Zhi. 2009 ; 47: 1185-1188
98. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 ; 275: 1943-1947
99. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997 ; 15: 356-362
100. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998: 273 13375-13378
101. Lee JO, Yang H, Georgescu MM, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999 ; 99: 323-334
102. Schwartzbauer G, Robbins J. The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J Biol Chem. 2001 ; 276: 35786-35793
103. Schmid AC, Byrne RD, Vilar R, et al. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 2004 ; 566: 35-38
104. Mocanu MM, Field DC, Yellon DM. A potential role for PTEN in the diabetic heart. Cardiovasc Drugs Ther. 2006 ; 20: 319-321
105. Stambolic V, Suzuki A, De La Pompa, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998 ; 95: 29-39
106. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?. J Am Coll Cardiol. 2005 ; 45: 1287-1291
107. Keyes KT, Xu J, Long B, et al. Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function post-infarction. Am J Physiol Heart Circ Physiol. 2010 ; 298: H1198 - H1208
108. Tian Y, Daoud A, Shang J. Effects of bpV(pic) and bpV(phen) on H9c2 cardiomyoblasts during both hypoxia/reoxygenation and H2O2-induced injuries. Mol Med Report. 2011 ; 5: 852-858
109. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: clinical implications of recent trials. Am J Med. 1998 ; 104: S2 - S5
110. Grundy SM, Cleeman JI, Merz CN. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 ; 110: 227-239
111. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J. 2004 ; 148: 7-15
112. Hoshida S, Yamashita N, Igarashi J, et al. A nitric oxide donor reverses myocardial injury in rabbits with acute hypercholesterol. J Pharmacol Exp Ther. 1996 ; 278: 741-746
113. Jung O, Jung W, Malinski T, et al. Ischemic preconditioning and infarct mass: effect of hypercholesterolemia and endothelial dysfunction. Clin Exp Hypertens. 2000 ; 22: 165-179
114. Kurose I, Wolf RE, Grisham MB, et al. Hypercholesterolemia enhances oxidant production in mesenteric venules exposed to ischemia/reperfusion. Arterioscler Thromb Vasc Biol. 1998 ; 18: 1583-1588
115. Ohara Y, Peterson TE, Sayegh HS, et al. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation. 1995 ; 92: 892-903
116. Szilvassy Z, Csont T, Pali T, et al. Nitric oxide, peroxynitrile and cGMP in atherosclerosis - induced hypertension in rabbits: beneficial effects of cicletanine. J Vasc Res. 2001 ; 38: 39-46
117. Ferdinandy P, Szilvassy Z, Horvath LI, et al. Loss of pacing - induced preconditioning in rat hearts: role of nitric oxide and cholesterol-enriched diet. J Mol Cell Cardiol. 1997 ; 29: 3321-3333
118. Ueda Y, Kitakaze M, Komamura K, et al. Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol. 1999 ; 34: 2120-2125
119. Le Grand B, Viea B, Faurea P, et al. Increased resistance to ischemic injury in isolated perfused atherosclerotic heart of cholesterol-fed rabbit. Cardiovasc Res. 1995 ; 30: 689-696
120. Ferdinandy P, Csonka C, Csont T, et al. Rapid pacing induced preconditioning is recaptured by farnesol treatment in hearts of cholesterol-fed rats: role of polyprenyl-derivatives and nitric oxide. Mol Cell Biochem. 1998 ; 186: 27-34
121. Girod WG, Jones SP, Sieber N, et al. Effects of hypercholesterolemia on myocardial ischemia-reperfusion injury in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 1999 ; 19: 2776-2781
122. Kremestinos DT, Bofilis E, Karavolias GK, et al. Preconditioning limits myocardial infarct size in hypercholesterolemic rabbits. Atherosclerosis. 2000 ; 150: 81-89
123. Kocic I, Konstanski M, Dworkaowska D, et al. Experimental hyperlipidemia prevents the protective effect of ischemic preconditioning on the contractility and responsiveness to phenylephrine of rat-isolated stunned papillary muscle. Gen Pharmacol. 1999 ; 33: 213-219
124. Kyriakides ZS, Psychari S, Ilidromitis EK, et al. Hyperlipidemia prevents expected reduction of myocardial ischemia on repeated balloon inflations during angioplasty. Chest. 2002 ; 121: 1211-1215
125. Genda S, Miura T, Miki T, et al. KATP channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol. 2002 ; 40: 1339-1346
126. Puskas LG, Nagy ZB, Giricz Z, et al. Cholesterol diet-induced hyperlipidemia influences gene expression pattern of rat hearts: a DNA microarray study. FEBS Lett. 2004 ; 562: 99-104
127. Csont T, Bereczki E, Bencsik P, et al. Hypercholesterolemia increases myocardial oxidative and nitrosative stress thereby leading to cardiac dysfunction in apoB-100 transgenic mice. Cardiovasc Res. 2007 ; 76: 100-109
128. Wang TD, Chen WJ, Su SS, et al. Increased cardiomyocyte apoptosis following ischemia and reperfusion in diet-induced hypercholesterolemia: relation to Bcl-2 and Bax proteins and caspase-3 activity. Lipids. 2002 ; 37: 385-394
129. Onody A, Csonka C, Giricz Z, et al. Hyperlipidemia induced by a cholesterol-rich diet leads to enhanced peroxynitrile formation in rat hearts. Cardiovasc Res. 2003 ; 58: 663-670
130. Csont T, Balogh G, Csonka C, et al. Hyperlipidemia induced by high cholesterol diet inhibits heat shock response in rat hearts. Biochem Biophys Res Commun. 2002 ; 290: 1535-1538
131. Guilland JC, Favier A, Potier de, Courcy G, et al. Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease? 1. Basic data. Pathol Biol. 2003 ; 51: 101-110
132. Sandberg EM, Sayeski PP. Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem. 2004 ; 279: 34547-34552
133. Simon AR, Rai U, Fanburg BL, et al. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol Cell Physiol. 1998 ; 275: 1640-1652
134. SchieŠer B, Luchtefeld M, Braun S, et al. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res. 2000 ; 87: 1195-1201
135. Zecchin HG, De Souza CT, Prada PO, et al. Effect of obesity on insulin signaling through JAK2 in rat aorta. Vasc Pharmacol. 2005 ; 43: 346-352
136. Mascareno E, El-Shafei M, Maulik N, et al. JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation. 2001 ; 104: 325-329